NDATOPICALSYSTEM
Approved
Jan 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
FLECTOR (diclofenac epolamine) by IBSA Institut Biochimique is analgesic, anti-inflammatory, and antipyretic properties. First approved in 2007.
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLECTOR is a topical diclofenac epolamine patch approved in 2007 for localized pain and inflammation. It is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes to reduce prostaglandin synthesis, thereby decreasing pain and inflammation at the site of application. The transdermal system delivers diclofenac directly to affected tissues while minimizing systemic exposure.
$0.002BPart D
LOE ApproachingDeclining
Modest commercial footprint with $2M Part D spending signals a mature, niche topical product approaching loss of exclusivity; brand teams should expect resource constraints and focus on defensive positioning.
Mechanism of Action
analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of diclofenac, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Diclofenac is a potent inhibitor of prostaglandin synthesis in vitro. Diclofenac…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries
Started May 2014
104 enrolled
Athletic Injuries
Study to Assess the Effectiveness and Safety of FLECTOR Patch for Treatment of Acute Back Strain
Started Jan 2010
123 enrolled
Acute Back Strain
Career Relevance
Worked on FLECTOR at IBSA Institut Biochimique? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.